Faron Pharmaceuticals Oy Asset Resilience Ratio
Faron Pharmaceuticals Oy asset resilience ratio. Faron Pharmaceuticals Oy (FARN) has an Asset Resilience Ratio of 0.11% as of June 2018. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See FARN cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Faron Pharmaceuticals Oy (None–None)
Asset resilience ratio of Faron Pharmaceuticals Oy from None to None. This chart shows how Faron Pharmaceuticals Oy's Asset Resilience Ratio has changed over time. Read Faron Pharmaceuticals Oy (FARN) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Faron Pharmaceuticals Oy's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Faron Pharmaceuticals Oy balance sheet assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | GBX0.00 | 0% |
| Short-term Investments | GBX17.98K | 0.11% |
| Total Liquid Assets | GBX17.98K | 0.11% |
Asset Resilience Insights
- Limited Liquidity: Faron Pharmaceuticals Oy maintains only 0.11% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Faron Pharmaceuticals Oy Industry Peers by Asset Resilience Ratio
Compare Faron Pharmaceuticals Oy's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940 |
Biotechnology | 15.21% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821 |
Biotechnology | 5.07% |
|
Immunovant Inc
NASDAQ:IMVT |
Biotechnology | 98.50% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Amicus Therapeutics Inc
NASDAQ:FOLD |
Biotechnology | 8.37% |
Faron Pharmaceuticals Oy Asset Resilience Ratio by Year (None–None)
Faron Pharmaceuticals Oy asset resilience ratio by year from None to None. The table below shows the annual Asset Resilience Ratio data for Faron Pharmaceuticals Oy.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| No yearly data available. | ||||
About Faron Pharmaceuticals Oy
Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. Its lead product candidates are Traumakine, an investigational intravenous interferon beta-1a therapy for the prevention from cytokine release syndrome (CRS), or ischemia and hyperinflammatory conditions; and Bexmarilimab, a novel anti-Clever-1 humanized antibody that targets a subpopulation of tumor-ass… Read more